Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on November 25, 2026 | For discussion with your oncologist

TRIAL

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

NCT ID: NCT05907954 Phase: PHASE2 Sponsor: IDEAYA Biosciences Status: Active Not Recruiting

SUMMARY

Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma

KEY ELIGIBILITY CRITERIA

- * Primary localized uveal melanoma requiring either enucleation or plaque brachytherapy
- * Cohort 3 (patients with small UM tumors) - clinically diagnosed uveal (not iris) melanoma that is \< 4 mm in thickness requiring treatment
- * Able to dose orally
- * ECOG Performance status of 0-1
- * No other significant underlying ocular disease
- * Adequate organ function
- * Not pregnant/nursing or planning to become pregnant. Willing to use birth control
- * Previous treatment with a Protein Kinase C (PKC) inhibitor
- * Concurrent malignant disease
- * Active HIV infection or Hep B/C

Total sites: 18 | 0 currently recruiting

This document is for informational purposes only and does not constitute medical advice. Always discuss clinical trial decisions with your oncologist. Data sourced from ClinicalTrials.gov (NCT05907954) and public sources. Generated by FindMyCure.ai.